大肠癌组织中联合检测USP22和BMI-1表达的临床意义  

Clinical Significance of the Expression of USP22 and BMI-1in Colorectal Cancer

作　　者：孙梓程[1] 崔滨滨[1] 刘彦龙[1] 张干[1] 李景文[1] 韩鹏[1] 

机构地区：[1]哈尔滨医科大学附属肿瘤医院结直肠外科,黑龙江哈尔滨150001

出　　处：《现代生物医学进展》2014年第33期6432-6436,共5页Progress in Modern Biomedicine

基　　金：国家自然基金面上项目(81272704);黑龙江省自然科学基金面上项目(D201149)

摘　　要：目的:探讨大肠癌组织中联合检测USP22和BMI-1表达的临床意义。方法:应用定量RT-PCR检测82例大肠癌手术切除标本及相应的癌旁组织中USP22及BMI-1 mRNA的表达水平,并分析其表达的差异,研究其表达水平与大肠癌患者临床病理特征及预后的关系。结果:USP22、BMI-1 mRNA在大肠癌及癌旁组织中均可被检出,大肠癌组织中USP22、BMI-1 mRNA的相对表达水平均显著高于癌旁组织(P<0.01),且二者之间呈显著正相关(r=0.708,P<0.01)。USP22、BMI-1 mRNA的高表达均与大肠癌的美国癌症分期联合委员会(AJCC)分期密切相关(P<0.01)。COX回归分析显示USP22及BMI-1的共表达可作为大肠癌患者预后的独立预测因素(P<0.01)。结论:USP22和BMI-1的共同激活可促进大肠癌的进展,并预示预后不良。Objective： To investigate the clinical significances of expression of USP22 and BMI-1 in colorectal cancer（CRC）.Methods： The mRNA level of USP22, BMI-1 in 82 matched samples comprising primary CRC and paired non-cancerous mucosa were detected and compared by quantitative RT-PCR. Then the correlation of mRNA level of USP22, BMI-1 with the clinicopathological characteristics and prognosis of patients with CRC were analyzed. Results： The mRNA expression of USP22 and BMI-1 were significantly up-regulated from non-cancerous mucosa to primary carcinoma（P〈0.0001）. There was positive and significant relationship（r=0.708, P〈0.0001） between the two genes. Increased mRNA expression of USP22 and BMI-1 were associated with certain clinical-pathologic variables such as advancing AJCC stage（P〈0.0001）. Overexpression of USP22 and BMI-1 remained a statistically-significant prognostic marker in the Cox regression analysis. Conclusion： The co-activation of USP22 and BMI-1 may associate with the progression and prognosis of CRC.

关 键 词：USP22 BMI-1 大肠癌 临床病理特征 预后 

分 类 号：R735.34[医药卫生—肿瘤]